Microvast Holdings announces departure of chief financial officer
Britt J. Vitalone, Executive Vice President and Chief Financial Officer of McKesson Corp (NYSE:MCK), executed a sale of 1,878 shares of common stock on May 28, 2025. The shares were sold at a price of $717.91 each, amounting to a total transaction value of approximately $1.35 million. The transaction comes as McKesson, with a market capitalization of $89.2 billion, trades near its 52-week high of $731, having delivered an impressive 25% return year-to-date. Following this transaction, Vitalone holds 14,028.377 shares directly. This sale was conducted under a pre-established trading plan, in line with Rule 10b5-1(c), which had been adopted on November 9, 2024. Additionally, Vitalone has an indirect holding of 550.1757 shares through the McKesson Corporation 401(k) Retirement Savings Plan. According to InvestingPro analysis, McKesson maintains a "GREAT" financial health score, with 12+ additional exclusive insights available to subscribers, including detailed insider trading patterns and comprehensive valuation metrics.
In other recent news, McKesson Corporation announced a strong financial performance for the fiscal year 2025, with a 16% increase in full-year consolidated revenues reaching $359.1 billion. The company also achieved a 20% year-over-year growth in earnings per share (EPS), reflecting solid operational execution. However, during the third quarter of 2025, while McKesson’s adjusted EPS of $10.12 surpassed the forecast of $9.81, revenue fell short of expectations at $90.82 billion against a forecast of $93.48 billion. Looking ahead, McKesson has projected revenue growth of 11% to 15% for fiscal 2026, with an anticipated EPS range of $36.05 to $37.55.
Analyst Rob Dickerson from Jefferies raised McKesson’s stock target to $800, maintaining a Buy rating, following the company’s fourth-quarter earnings report that exceeded Wall Street’s expectations by 3%. McKesson’s long-term EPS growth outlook remains at 12% to 14%, and the company has increased its operating income growth projection for its U.S. Pharmaceutical (TADAWUL:2070) segment by 100 basis points. Strategic acquisitions, including controlling interests in Prism Vision and CORE Ventures, continue to bolster McKesson’s growth in the healthcare services sector. Additionally, McKesson plans to separate its Medical (TASE:BLWV) Surgical segment into an independent entity to enhance focus and operational efficiency. These recent developments underscore McKesson’s strong financial position and strategic advancements in the healthcare industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.